Scotiabank raised the firm’s price target on Apellis (APLS) to $31 from $30 and keeps a Sector Perform rating on the shares. The company recently announced FDA acceptance of its supplementary new drug application for Empaveli and was granted Priority Review designation for treatment of C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, the analyst tells investors. The company anticipates launching in 2H25 and expects the drug’s broad efficacy profile to support robust uptake despite the recent entry of a competitor, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Promising Outlook for Apellis Pharmaceuticals: Buy Rating Backed by Key Milestones and Attractive Valuation
- Apellis announces FDA acceptance, priority review of sNDA for EMPAVELI
- Cautious Hold on Apellis Pharmaceuticals Amid Competitive Landscape and Promising Empaveli Prospects
- Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli
- Apellis Pharmaceuticals: Favorable Market Positioning and Strong Clinical Results Justify Buy Rating